Functional screening of lysosomal storage disorder genes identifies modifiers of alpha-synuclein mediated neurodegeneration
Meigen YuiD, Hui YeiD, Ruth B. De-PaulaiD, Carl Grant MangleburgiD, Timothy WuiD, Yarong LiiD, Duc M. DuongiD, Genevera I. AlleniD, Nicholas T. SeyfriediD, Ismael Al‐RamahiiD, Juan BotasiD, Joshua M ShulmaniD
Abstract
Heterozygous variants in the glucocerebrosidase (GBA) gene are common and potent risk factors for Parkinsons disease (PD). GBA also causes the autosomal recessive lysosomal storage disorder (LSD), Gaucher disease, and emerging evidence from human genetics implicates many other LSD genes in PD susceptibility. We have systemically tested 88 conserved fly homologs of 38 human LSD genes for requirements in the aging adult Drosophila brain and for potential genetic interactions with neurodegeneration caused by -synuclein (Syn), which forms Lewy body pathology in PD. Our screen identifies 15 genetic enhancers of Syn-induced progressive locomotor dysfunction, following knockdown of fly homologs of GBA and other LSD genes with independent support as PD susceptibility factors from human genetics (SCARB2, SMPD1, CTSD, GNPTAB, SLC17A5). For several genes, results from multiple alleles support dose-sensitivity and context-dependent pleiotropy in the presence or absence of Syn. Homologs of 2 genes causing cholesterol storage disorders, Npc1a / NPC1 and Lip4 / LIPA, were independently confirmed as loss-of-function enhancers of Syn-induced brain structural degeneration. The enzymes encoded by several modifier genes are upregulated in Syn transgenic flies, based on unbiased proteomics, revealing a possible compensatory response. Overall, our results reinforce the important role of lysosomal genes in brain health and PD pathogenesis, and implicate several metabolic pathways, including cholesterol homeostasis, in Syn-mediated neurodegeneration.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neuronopathic GBA1 L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions
Casey L. Mahoney-Crane, Megha Viswanathan, … Laura A. Volpicelli‐Daley·Journal of NeurosciencePeer-reviewed·Dec 7, 2022
- Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson's disease
Cheryl E. G. Leyns, Alice Prigent, … Michael X. Henderson·npj Parkinson s DiseasePeer-reviewed·May 11, 2023
- Synaptic vesicle endocytosis deficits underlie GBA-linked cognitive dysfunction in Parkinson's disease and Dementia with Lewy bodies
D. J. Vidyadhara, David C. Bäckström, … Sreeganga S. Chandra·bioRxiv·Oct 23, 2024
- Shared and Distinct Lipid Profiles in amygdala from Sporadic and GBA-associated Parkinson's Diseases
Sonia Sanz Muñoz, Frederik Ravnkilde Marlet, … Céline Galvagnion·npj Parkinson s DiseasePeer-reviewed·May 11, 2026
- Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation
C. Galvagnion, S. Cerri, … D. A. Di Monte·BrainPeer-reviewed·Apr 1, 2022
- The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines.
Laura J Smith, Magdalena M. Bolsinger, … Anthony H.V. Schapira·Human Molecular GeneticsPeer-reviewed·Sep 18, 2022